{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:34:08Z","timestamp":1793741648921,"version":"4.6.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T00:00:00Z","timestamp":1550448000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T00:00:00Z","timestamp":1550448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["RF1AG054057"],"award-info":[{"award-number":["RF1AG054057"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["R21E2021290"],"award-info":[{"award-number":["R21E2021290"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1038\/s41380-019-0375-7","type":"journal-article","created":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T08:03:00Z","timestamp":1550476980000},"page":"2932-2941","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":355,"title":["Brain iron is associated with accelerated cognitive decline in people with Alzheimer pathology"],"prefix":"10.1038","volume":"25","author":[{"given":"Scott","family":"Ayton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahima","family":"Diouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Brockman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha Clare","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8259-9069","authenticated-orcid":false,"given":"Ashley I.","family":"Bush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,18]]},"reference":[{"key":"375_CR1","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X","volume":"45","author":"JL Price","year":"1999","unstructured":"Price JL, Morris JC. Tangles and plaques in nondemented aging and \u201cpreclinical\u201d Alzheimer\u2019s disease. Ann Neurol. 1999;45:358\u201368.","journal-title":"Ann Neurol"},{"key":"375_CR2","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1001\/archneur.65.11.1509","volume":"65","author":"HJ Aizenstein","year":"2008","unstructured":"Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65:1509\u201317.","journal-title":"Arch Neurol"},{"key":"375_CR3","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1212\/01.wnl.0000219668.47116.e6","volume":"66","author":"DA Bennett","year":"2006","unstructured":"Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66:1837\u201344.","journal-title":"Neurology"},{"key":"375_CR4","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1212\/01.wnl.0000228230.26044.a4","volume":"67","author":"MA Mintun","year":"2006","unstructured":"Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446\u201352.","journal-title":"Neurology"},{"key":"375_CR5","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/ana.24040","volume":"74","author":"CC Rowe","year":"2013","unstructured":"Rowe CC, Bourgeat P, Ellis KA, Brown B, Lim YY, Mulligan R, et al. Predicting Alzheimer disease with beta-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing. Ann Neurol. 2013;74:905\u201313.","journal-title":"Ann Neurol"},{"key":"375_CR6","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.21610","volume":"65","author":"LM Shaw","year":"2009","unstructured":"Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer\u2019s disease neuroimaging initiative subjects. Ann Neurol. 2009;65:403\u201313.","journal-title":"Ann Neurol"},{"key":"375_CR7","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1212\/01.wnl.0000267428.62582.aa","volume":"69","author":"G Li","year":"2007","unstructured":"Li G, Sokal I, Quinn JF, Leverenz JB, Brodey M, Schellenberg GD, et al. CSF tau\/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology. 2007;69:631\u20139.","journal-title":"Neurology"},{"key":"375_CR8","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/archneur.64.3.noc60123","volume":"64","author":"AM Fagan","year":"2007","unstructured":"Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau\/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64:343\u20139.","journal-title":"Arch Neurol"},{"issue":"Pt 1","key":"375_CR9","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/brain\/awt286","volume":"137","author":"YY Lim","year":"2014","unstructured":"Lim YY, Maruff P, Pietrzak RH, Ames D, Ellis KA, Harrington K, et al. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer\u2019s disease. Brain. 2014;137(Pt 1):221\u201331.","journal-title":"Brain"},{"key":"375_CR10","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3233\/JAD-140396","volume":"42","author":"Y Tao","year":"2014","unstructured":"Tao Y, Wang Y, Rogers JT, Wang F. Perturbed iron distribution in Alzheimer\u2019s disease serum, cerebrospinal fluid, and selected brain regions: a systematic review and meta-analysis. J Alzheimer\u2019s Dis. 2014;42:679\u201390.","journal-title":"J Alzheimer\u2019s Dis"},{"key":"375_CR11","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/mds.23971","volume":"27","author":"SA Schneider","year":"2012","unstructured":"Schneider SA, Hardy J, Bhatia KP. Syndromes of neurodegeneration with brain iron accumulation (NBIA): an update on clinical presentations, histological and genetic underpinnings, and treatment considerations. Mov Disord. 2012;27:42\u201353.","journal-title":"Mov Disord"},{"key":"375_CR12","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","volume":"171","author":"BR Stockwell","year":"2017","unstructured":"Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171:273\u201385.","journal-title":"Cell"},{"key":"375_CR13","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms7760","volume":"6","author":"S Ayton","year":"2015","unstructured":"Ayton S, Faux NG, Bush AI. Alzheimer\u2019s Disease Neuroimaging Initiative I. Ferritin levels in the cerebrospinal fluid predict Alzheimer\u2019s disease outcomes and are regulated by APOE. Nat Commun. 2015;6:6760.","journal-title":"Nat Commun"},{"key":"375_CR14","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1001\/jamaneurol.2016.4406","volume":"74","author":"S Ayton","year":"2017","unstructured":"Ayton S, Faux NG, Bush AI. Association of cerebrospinal fluid ferritin level with preclinical cognitive decline in APOE-epsilon4 carriers. JAMA Neurol. 2017;74:122\u20135.","journal-title":"JAMA Neurol"},{"key":"375_CR15","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1093\/brain\/awx137","volume":"140","author":"S Ayton","year":"2017","unstructured":"Ayton S, Fazlollahi A, Bourgeat P, Raniga P, Ng A, Lim YY, et al. Cerebral quantitative susceptibility mapping predicts amyloid-beta-related cognitive decline. Brain. 2017;140:2112\u20139.","journal-title":"Brain"},{"key":"375_CR16","doi-asserted-by":"crossref","first-page":"646","DOI":"10.2174\/156720512801322663","volume":"9","author":"DA Bennett","year":"2012","unstructured":"Bennett DA, Schneider JA, Buchman AS, Barnes LL, Boyle PA, Wilson RS. Overview and findings from the rush Memory and Aging Project. Curr Alzheimer Res. 2012;9:646\u201363.","journal-title":"Curr Alzheimer Res"},{"key":"375_CR17","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology. 1984;34:939\u201344.","journal-title":"Neurology"},{"issue":"Pt 10","key":"375_CR18","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1093\/brain\/aws234","volume":"135","author":"JA Schneider","year":"2012","unstructured":"Schneider JA, Arvanitakis Z, Yu L, Boyle PA, Leurgans SE, Bennett DA. Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies. Brain. 2012;135(Pt 10):3005\u201314.","journal-title":"Brain"},{"key":"375_CR19","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1161\/STROKEAHA.110.595082","volume":"42","author":"Z Arvanitakis","year":"2011","unstructured":"Arvanitakis Z, Leurgans SE, Barnes LL, Bennett DA, Schneider JA. Microinfarct pathology, dementia, and cognitive systems. Stroke. 2011;42:722\u20137.","journal-title":"Stroke"},{"key":"375_CR20","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0022-510X(95)00018-W","volume":"130","author":"DL Samudralwar","year":"1995","unstructured":"Samudralwar DL, Diprete CC, Ni BF, Ehmann WD, Markesbery WR. Elemental imbalances in the olfactory pathway in Alzheimer\u2019s disease. J Neurol Sci. 1995;130:139\u201345.","journal-title":"J Neurol Sci"},{"key":"375_CR21","doi-asserted-by":"crossref","first-page":"9866","DOI":"10.1073\/pnas.94.18.9866","volume":"94","author":"MA Smith","year":"1997","unstructured":"Smith MA, Harris PL, Sayre LM, Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA. 1997;94:9866\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"375_CR22","doi-asserted-by":"crossref","DOI":"10.1038\/srep24873","volume":"6","author":"G Plascencia-Villa","year":"2016","unstructured":"Plascencia-Villa G, Ponce A, Collingwood JF, Arellano-Jimenez MJ, Zhu X, Rogers JT, et al. High-resolution analytical imaging and electron holography of magnetite particles in amyloid cores of Alzheimer\u2019s disease. Sci Rep. 2016;6:24873.","journal-title":"Sci Rep"},{"key":"375_CR23","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.3233\/JAD-161143","volume":"60","author":"S van Duijn","year":"2017","unstructured":"van Duijn S, Bulk M, van Duinen SG, Nabuurs RJA, van Buchem MA, van der Weerd L, et al. Cortical iron reflects severity of Alzheimer\u2019s disease. J Alzheimer\u2019s Dis. 2017;60:1533\u201345.","journal-title":"J Alzheimer\u2019s Dis"},{"key":"375_CR24","doi-asserted-by":"publisher","unstructured":"Ayton S, Diouf I, Bush AI, Alzheimer\u2019s disease Neuroimaging I. Evidence that iron accelerates Alzheimer\u2019s pathology: a CSF biomarker study. J Neurol Neurosurg Psychiatry. 2017. https:\/\/doi.org\/10.1136\/jnnp-2017-316551.","DOI":"10.1136\/jnnp-2017-316551"},{"key":"375_CR25","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","volume":"71","author":"PT Nelson","year":"2012","unstructured":"Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71:362\u201381.","journal-title":"J Neuropathol Exp Neurol"},{"key":"375_CR26","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/nbm.3247","volume":"28","author":"MD Meadowcroft","year":"2014","unstructured":"Meadowcroft MD, Peters DG, Dewal RP, Connor JR, Yang QX. The effect of iron in MRI and transverse relaxation of amyloid-beta plaques in Alzheimer\u2019s disease. NMR Biomed. 2014;28:297\u2013305.","journal-title":"NMR Biomed"},{"key":"375_CR27","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.chembiol.2017.10.002","volume":"24","author":"S Ayton","year":"2017","unstructured":"Ayton S, James SA, Bush AI. Nanoscale imaging reveals big role for iron in Alzheimer\u2019s disease. Cell Chem Biol. 2017;24:1192\u20134.","journal-title":"Cell Chem Biol"},{"key":"375_CR28","doi-asserted-by":"publisher","unstructured":"Telling ND, Everett J, Collingwood JF, Dobson J, van der Laan G, Gallagher JJ et al. Iron biochemistry is correlated with amyloid plaque morphology in an established mouse model of Alzheimer\u2019s disease. Cell Chem Biol. 2017. https:\/\/doi.org\/10.1016\/j.chembiol.2017.1007.1014.","DOI":"10.1016\/j.chembiol.2017.1007.1014."},{"key":"375_CR29","doi-asserted-by":"crossref","unstructured":"Everett J, Collingwood JF, Tjendana-Tjhin V, Brooks J, Lermyte F, Plascencia-Villa G et al. Nanoscale synchrotron X-ray speciation of iron and calcium compounds in amyloid plaque cores from Alzheimer\u2019s disease subjects. Nanoscale 2018;10:11782\u201396.","DOI":"10.1039\/C7NR06794A"},{"key":"375_CR30","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1136\/jnnp-2017-316551","volume":"89","author":"S Ayton","year":"2018","unstructured":"Ayton S, Diouf I, Bush AI. Alzheimer\u2019s disease Neuroimaging I. Evidence that iron accelerates Alzheimer\u2019s pathology: a CSF biomarker study. J Neurol Neurosurg Psychiatry. 2018;89:456\u201360.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"375_CR31","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nm.2613","volume":"18","author":"P Lei","year":"2012","unstructured":"Lei P, Ayton S, Finkelstein DI, Spoerri L, Ciccotosto GD, Wright DK, et al. Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med. 2012;18:291\u20135.","journal-title":"Nat Med"},{"key":"375_CR32","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1007\/s13311-015-0378-2","volume":"12","author":"X Li","year":"2015","unstructured":"Li X, Lei P, Tuo Q, Ayton S, Li QX, Moon S, et al. Enduring elevations of hippocampal amyloid precursor protein and iron are features of beta-amyloid toxicity and are mediated by tau. Neurother: J Am Soc Exp Neurother. 2015;12:862\u201373.","journal-title":"Neurother: J Am Soc Exp Neurother"},{"key":"375_CR33","volume":"6","author":"JM van Bergen","year":"2016","unstructured":"van Bergen JM, Li X, Hua J, Schreiner SJ, Steininger SC, Quevenco FC, et al. Colocalization of cerebral iron with Amyloid beta in Mild Cognitive Impairment. Sci Rep. 2016;6:35514.","journal-title":"Sci Rep"},{"key":"375_CR34","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","volume":"14","author":"MT Heneka","year":"2015","unstructured":"Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer\u2019s disease. Lancet Neurol. 2015;14:388\u2013405.","journal-title":"Lancet Neurol"},{"key":"375_CR35","doi-asserted-by":"crossref","unstructured":"Zeineh MM, Chen Y, Kitzler HH, Hammond R, Vogel H, Rutt BK. Activated iron-containing microglia in the human hippocampus identified by magnetic resonance imaging in Alzheimer disease. Neurobiol Aging. 2015;36:2483\u2013500.","DOI":"10.1016\/j.neurobiolaging.2015.05.022"},{"key":"375_CR36","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1146\/annurev.nutr.012809.104804","volume":"30","author":"M Wessling-Resnick","year":"2010","unstructured":"Wessling-Resnick M. Iron homeostasis and the inflammatory response. Annu Rev Nutr. 2010;30:105\u201322.","journal-title":"Annu Rev Nutr"},{"issue":"Pt 9","key":"375_CR37","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1093\/brain\/awt188","volume":"136","author":"JB Toledo","year":"2013","unstructured":"Toledo JB, Arnold SE, Raible K, Brettschneider J, Xie SX, Grossman M, et al. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer\u2019s Coordinating Centre. Brain. 2013;136(Pt 9):2697\u2013706.","journal-title":"Brain"},{"key":"375_CR38","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1148\/radiol.11110251","volume":"262","author":"T Liu","year":"2012","unstructured":"Liu T, Surapaneni K, Lou M, Cheng L, Spincemaille P, Wang Y. Cerebral microbleeds: burden assessment by using quantitative susceptibility mapping. Radiology. 2012;262:269\u201378.","journal-title":"Radiology"},{"key":"375_CR39","first-page":"59","volume":"11","author":"SA Schneider","year":"2013","unstructured":"Schneider SA, Dusek P, Hardy J, Westenberger A, Jankovic J, Bhatia KP. Genetics and pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA). Curr Neuropharmacol. 2013;11:59\u201379.","journal-title":"Curr Neuropharmacol"},{"key":"375_CR40","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.nbd.2007.12.007","volume":"30","author":"T Reed","year":"2008","unstructured":"Reed T, Perluigi M, Sultana R, Pierce WM, Klein JB, Turner DM, et al. Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer\u2019s disease. Neurobiol Dis. 2008;30:107\u201320.","journal-title":"Neurobiol Dis"},{"key":"375_CR41","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0304-3940(90)90226-Y","volume":"112","author":"I Hajimohammadreza","year":"1990","unstructured":"Hajimohammadreza I, Brammer M. Brain membrane fluidity and lipid peroxidation in Alzheimer\u2019s disease. Neurosci Lett. 1990;112:333\u20137.","journal-title":"Neurosci Lett"},{"key":"375_CR42","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/j.freeradbiomed.2010.02.016","volume":"48","author":"MA Bradley","year":"2010","unstructured":"Bradley MA, Markesbery WR, Lovell MA. Increased levels of 4-hydroxynonenal and acrolein in the brain in preclinical Alzheimer disease. Free Radic Biol Med. 2010;48:1570\u20136.","journal-title":"Free Radic Biol Med"},{"key":"375_CR43","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.neurobiolaging.2005.06.004","volume":"27","author":"TI Williams","year":"2006","unstructured":"Williams TI, Lynn BC, Markesbery WR, Lovell MA. Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer\u2019s disease. Neurobiol Aging. 2006;27:1094\u20139.","journal-title":"Neurobiol Aging"},{"key":"375_CR44","doi-asserted-by":"crossref","first-page":"510","DOI":"10.5858\/2001-125-0510-CFATAF","volume":"125","author":"TJ Montine","year":"2001","unstructured":"Montine TJ, Kaye JA, Montine KS, McFarland L, Morrow JD, Quinn JF. Cerebrospinal fluidabeta42, tau, and f2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls. Arch Pathol Lab Med. 2001;125:510\u20132.","journal-title":"Arch Pathol Lab Med"},{"key":"375_CR45","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/ana.20629","volume":"58","author":"WR Markesbery","year":"2005","unstructured":"Markesbery WR, Kryscio RJ, Lovell MA, Morrow JD. Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann Neurol. 2005;58:730\u20135.","journal-title":"Ann Neurol"},{"key":"375_CR46","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.biopsych.2015.04.005","volume":"78","author":"PK Mandal","year":"2015","unstructured":"Mandal PK, Saharan S, Tripathi M, Murari G. Brain glutathione levels\u2013a novel biomarker for mild cognitive impairment and Alzheimer\u2019s disease. Biol Psychiatry. 2015;78:702\u201310.","journal-title":"Biol Psychiatry"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41380-019-0375-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41380-019-0375-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41380-019-0375-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T16:59:50Z","timestamp":1684601990000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-019-0375-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,18]]},"references-count":46,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["375"],"URL":"https:\/\/doi.org\/10.1038\/s41380-019-0375-7","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,18]]},"assertion":[{"value":"15 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AIB is a shareholder in Prana Biotechnology Ltd, Cogstate Ltd, Brighton Biotech LLC, Grunbiotics Pty Ltd, Eucalyptus Pty Ltd, and Mesoblast Ltd. He is a paid consultant for, and has a profit share interest in, Collaborative Medicinal Development Pty Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}